148672-13-3

Basic information

• Product Name: N-[4-METHOXY-3-(4-METHYLPIPERAZIN-1-YL)-PHENYL]-4-[2-METHYL-4-(5-METHYL-1,2,4-OXADIAZOL-3-YL)PHENYL]BENZAMIDE
• Synonyms: N-[4-METHOXY-3-(4-METHYL-1-PIPERAZINYL)PHENYL]-2'-METHYL-4'-(5-METHYL-1,2,4-OXADIAZOL-3-YL)-1,1'-BIPHENYL-4-CARBOXAMIDE HYDROCHLORIDE;N-[4-METHOXY-3-(4-METHYLPIPERAZIN-1-YL)-PHENYL]-4-[2-METHYL-4-(5-METHYL-1,2,4-OXADIAZOL-3-YL)PHENYL]BENZAMIDE;GR 127935 HYDROCHLORIDE HYDRATE;GR127935HCl;N-[4-Methoxy-3-(4-methyl-1-piperazinyl)phenyl]-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)-1,1'-biphenyl-4-carboxamide;GR 127935;N-[4-Methoxy-3-(4-methyl-1-piperazinyl)phenyl]-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)-1,1'-biphenyl-4-carboxamide hydrochloride;N-[4-Methoxy-3-(4-methylpiperazin-1-yl)-phenyl]-4-[2-methyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)phen
• CAS NO: 148672-13-3
• Molecular Formula: C₂₉H₃₁N₅O₃
• Molecular Weight: 497.59
• Mol File: 148672-13-3.mol
• Article Data: 3

Chemical Properties

• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: white/solid
• Density: 1.219g/cm³
• Refractive Index: 1.619
• Storage Temp.: 2-8°C
• Solubility: H2O: 14 mg/mL, soluble
• PKA: 12.55±0.70(Predicted)
• CAS DataBase Reference: N-[4-METHOXY-3-(4-METHYLPIPERAZIN-1-YL)-PHENYL]-4-[2-METHYL-4-(5-METHYL-1,2,4-OXADIAZOL-3-YL)PHENYL]BENZAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N-[4-METHOXY-3-(4-METHYLPIPERAZIN-1-YL)-PHENYL]-4-[2-METHYL-4-(5-METHYL-1,2,4-OXADIAZOL-3-YL)PHENYL]BENZAMIDE(148672-13-3)
• EPA Substance Registry System: N-[4-METHOXY-3-(4-METHYLPIPERAZIN-1-YL)-PHENYL]-4-[2-METHYL-4-(5-METHYL-1,2,4-OXADIAZOL-3-YL)PHENYL]BENZAMIDE(148672-13-3)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 148672-13-3(Hazardous Substances Data)

Usage

Description

N-[4-METHOXY-3-(4-METHYLPIPERAZIN-1-YL)-PHENYL]-4-[2-METHYL-4-(5-METHYL-1,2,4-OXADIAZOL-3-YL)PHENYL]BENZAMIDE is a complex organic compound with a unique chemical structure. It is characterized by its benzamide core, with various substituents and functional groups that contribute to its potential applications in different fields.

Uses

Used in Pharmaceutical Industry:
N-[4-METHOXY-3-(4-METHYLPIPERAZIN-1-YL)-PHENYL]-4-[2-METHYL-4-(5-METHYL-1,2,4-OXADIAZOL-3-YL)PHENYL]BENZAMIDE is used as a pharmaceutical compound for its potential therapeutic effects. The compound's structure suggests that it may interact with specific biological targets, such as receptors or enzymes, which could be beneficial in the treatment of various medical conditions.
Used in Chemical Research:
In the field of chemical research, N-[4-METHOXY-3-(4-METHYLPIPERAZIN-1-YL)-PHENYL]-4-[2-METHYL-4-(5-METHYL-1,2,4-OXADIAZOL-3-YL)PHENYL]BENZAMIDE can be used as a starting material or a reference compound for the synthesis of other related molecules. Its unique structure may provide insights into the design and development of new chemical entities with improved properties and applications.
Used in Material Science:
The compound's specific structural features may also make it suitable for applications in material science, where it could be used to develop new materials with unique properties, such as improved stability, reactivity, or selectivity in various chemical processes.

Biological Activity

Potent and selective 5-HT 1B/1D receptor antagonist (pK i values are 8.5 for both guinea pig 5-HT 1D and rat 5-HT 1B receptors). Displays > 100-fold selectivity over 5HT 1A , 5-HT 2A , 5-HT 2C receptors and other receptor types. Centrally active following oral administration.

InChI:InChI=1/C29H31N5O3/c1-19-17-23(28-30-20(2)37-32-28)9-11-25(19)21-5-7-22(8-6-21)29(35)31-24-10-12-27(36-4)26(18-24)34-15-13-33(3)14-16-34/h5-12,17-18H,13-16H2,1-4H3,(H,31,35)

Upstream product

• 148672-39-3 3-(4'-bromo-3'-methylphenyl)-5-methyl-1,2,4-oxadiazole 
• 148547-21-1 [4-({[4-(methyloxy)-3-(4-methyl-1-piperazinyl)phenyl]amino}carbonyl)phenyl]boronic acid 
• 148546-79-6 4-Bromo-N-[4-methoxy-3-(4-methyl-piperazin-1-yl)-phenyl]-benzamide 

Downstream Products

• 256227-71-1 4'-carbamimidoyl-2'-methyl-biphenyl-4-carboxylic acid [4-methoxy-3-(4-methyl-piperazin-1-yl)-phenyl]-amide 
• 148672-37-1 N-[4-Hydroxy-3-(4-methyl-1-piperazinyl)phenyl]-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-carboxamide 

Relevant articles and documents

New selective and potent 5-HT(1B/1D) antagonists: Chemistry and pharmacological evaluation of N-piperazinylphenyl biphenylcarboxamides and biphenylsulfonamides

A series of new analogues of N-[4-methoxy-3-(4-methylpiperazin-1- yl)phenyl] 2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carboxamide (1; GR127935) as potent and selective 5-HT(1B/1D) antagonists were synthesized and evaluated pharmacologically. Their receptor binding profiles were comparable to that of 1. The 1,3,4-oxadiazole isomer 2 and the 4'- aminocarbonyl and 4'-amidinyl analogues (9 and 10) of 1 had higher affinities at the rat 5-HT(1B) receptor (IC50 = 0.93, 1.3, and 0.5 nM, respectively) and calf 5-HT(1D) receptor (IC50 = 37, 10, and 3 nM, respectively) than did 1 (1.6 and 52 nM for rat 5-HT(1B) and calf 5-HT(1D) receptors, respectively). In the functional in vitro testing of 5-HT(1B/1D) antagonistic properties, 2, 9, 10, 11b (Odemethylated derivative of 2), 13a (O-methylsulfonyl analogue of 2), and 16 (which differs from 2 with a sulfonamide linker) showed more pronounced effects in the K+-induced 5-HT release in the cortex of guinea pig than did 1 and 3 (SB224289). Compounds 2, 9, and 10 were equally potent as 1 in rabbit saphenous vein model (pA2 > 9). A biochemical study of 2 with in vivo microdialysis in the rat brain showed that it is capable of augmenting citalopram (a selective serotonin reuptake inhibitor, SSRI) induced 5-HT release in rat ventral hippocampus, while preventing the decrease in acetylcholine release elicited by citalopram administration. The molecular structure of 2 was determined by single-crystal X-ray analysis. The log P and log D values of these compounds were calculated. This study contributes to the SAR study of N-piperazinylphenyl biphenylcarboxamides as selective and potent 5-HT(1B/1D) antagonists.

Evolution of a novel series of [(N,N-dimethylamino)propyl]- and piperazinylbenzanilides as the first selective 5-HT(1D) antagonists

-